Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Glycosylation

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    13 result(s) found for: Glycosylation. Displaying page 1 of 1.
    EudraCT Number: 2005-005723-34 Sponsor Protocol Number: Adamson 001 Start Date*: 2006-03-23
    Sponsor Name:Dept of Medicine
    Full Title: Studies on the effect of hyperglycemia on the structure of the fibrin-gel and on the glycosylation of fibrin , and in what way the use of acetylsalicylic acid may interfere with this effect.
    Medical condition: Patients with type 1 diabetes, not on ASA for the last 6 months, without a history of bleeding disorder and with a normal trobocyte count.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001993-52 Sponsor Protocol Number: IMCOVAS Start Date*: 2021-05-20
    Sponsor Name:University of Antwerp
    Full Title: Assessment of the immunogenicity and safety of marketed vaccines for COVID-19 after regular schedule and adapted vaccine schedules and routes: BNT162b2 (Comirnaty®; Pfizer-BioNTech), mRNA-1273 Vacc...
    Medical condition: Coronavirus disease-19 (COVID-19)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2024-000202-16 Sponsor Protocol Number: MLB-01-003 Start Date*: 2024-05-31
    Sponsor Name:ML Bio Solutions
    Full Title: AN OPEN LABEL PHASE 2 STUDY OF BBP 418 IN PATIENTS WITH LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 2I (MLB 01 003)
    Medical condition: Limb Girdle Muscular Dystrophy 2I/R9
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2021-001357-31 Sponsor Protocol Number: IIV-478 Start Date*: 2021-05-03
    Sponsor Name:National Institute of Health and the Environment
    Full Title: Immune Responses Induced by Vaccination Against COVID-19 in Dutch healthy subjects
    Medical condition: Immune Responses Induced by Vaccination Against COVID-19 in Dutch healthy subjects
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2017-000810-44 Sponsor Protocol Number: FSJD-PMM2-2016 Start Date*: 2017-05-31
    Sponsor Name:Fundació Sant Joan de Déu
    Full Title: Phase II clinical trial to evaluate the effectiveness and safety of acetazolamide in the treatment of cerebellar syndrome in patients with PMM2-CDG deficiency.
    Medical condition: Cerebellar syndrome
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029205 - Nervous system disorders 10008072 Cerebellar syndrome PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000679-25 Sponsor Protocol Number: IIBSP-CAN-2016-16 Start Date*: 2016-05-31
    Sponsor Name:INSTITUT DE RECERCA HSCSP
    Full Title: A prospective, randomized, double-blind and placebo-controlled, parallel group, phase II study to compare the efficacy and safety of candesartan versus placebo on cognitive impairment associated wi...
    Medical condition: Parkinson's Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003547-24 Sponsor Protocol Number: 21CH134 Start Date*: 2021-08-25
    Sponsor Name:CHU de Saint Etienne
    Full Title: Factors influencing the COVID-19 vaccine immune response (reactogenicity and immunogenicity) according to age and presence or not of a past history of COVID-19. COVIMMUNAGE study
    Medical condition: Volunteer
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001597-33 Sponsor Protocol Number: 20081203 Start Date*: 2009-06-18
    Sponsor Name:University Medical Center Utrecht
    Full Title: Development of chronic disease in newly diagnosed Idiopathic Thrombocytopenic Purpura of Childhood. A randomized controlled study on the influence of treatment with intravenous gammaglobulin on the...
    Medical condition: Acute Idiopathic Thrombocytopenic Purpura (ITP) in children
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10023095 ITP LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-006669-40 Sponsor Protocol Number: CURACTA Start Date*: 2023-04-20
    Sponsor Name:Universitätsklinikum Erlangen
    Full Title: Plasma cell depletion as an approach to reset autoimmunity in rheumatoid arthritis
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-006562-20 Sponsor Protocol Number: JAKIPRA Start Date*: 2022-10-26
    Sponsor Name:Universitätsklinikum Erlangen
    Full Title: JAK Inhibition in PReclinical Arthritis
    Medical condition: Preclinical Phase of rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003877-91 Sponsor Protocol Number: TOLERA Start Date*: 2019-06-13
    Sponsor Name:Universitätsklinikum Erlangen
    Full Title: Sequential B cell/T cell therapy to re-induce humoral immune tolerance in ACPA-positive Rheumatoid Arthritis (TOLERA): a prospective randomized controlled open-label single-centre clinical trial in...
    Medical condition: Active rheumatoid arthritis with ACPA antibodies failing methotrexate
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-001949-20 Sponsor Protocol Number: 1.0 Start Date*: 2023-01-09
    Sponsor Name:ALBIMMUNE S.L.
    Full Title: Human albumin treatment in adult septic shock. A phase 2, multicenter, randomized, controlled study evaluating the immune response and organ failure.
    Medical condition: Septic Shock
    Disease: Version SOC Term Classification Code Term Level
    23.1 10021881 - Infections and infestations 10040070 Septic shock PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001923-11 Sponsor Protocol Number: Nef-202 Start Date*: 2012-10-17
    Sponsor Name:Pharmalink AB
    Full Title: A Multicentre, Interventional Treatment, Randomised, Double-Blind, Single Group Assignment, Placebo Controlled Study to Evaluate the Efficacy and Safety of Two Different Doses of Nefecon® in Primar...
    Medical condition: Primary IgA nephropathy patients at risk of developing end stage renal disease
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004857 10069341 Berger's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) CZ (Completed) DE (Completed) BE (Completed) SE (Completed) DK (Completed) IT (Completed) GB (Completed) NL (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 01:16:23 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA